BridgeBio Pharma (BBIO) Free Cash Flow (2019 - 2025)
Historic Free Cash Flow for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$110.0 million.
- BridgeBio Pharma's Free Cash Flow rose 3910.23% to -$110.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$585.9 million, marking a year-over-year decrease of 2976.19%. This contributed to the annual value of -$521.7 million for FY2024, which is 139.26% up from last year.
- As of Q3 2025, BridgeBio Pharma's Free Cash Flow stood at -$110.0 million, which was up 3910.23% from -$80.9 million recorded in Q2 2025.
- BridgeBio Pharma's Free Cash Flow's 5-year high stood at $74.6 million during Q2 2024, with a 5-year trough of -$220.2 million in Q1 2024.
- In the last 5 years, BridgeBio Pharma's Free Cash Flow had a median value of -$135.9 million in 2022 and averaged -$125.1 million.
- In the last 5 years, BridgeBio Pharma's Free Cash Flow tumbled by 24605.69% in 2023 and then surged by 16565.61% in 2024.
- BridgeBio Pharma's Free Cash Flow (Quarter) stood at -$136.4 million in 2021, then skyrocketed by 31.07% to -$94.0 million in 2022, then crashed by 33.19% to -$125.3 million in 2023, then crashed by 55.98% to -$195.4 million in 2024, then soared by 43.67% to -$110.0 million in 2025.
- Its Free Cash Flow stands at -$110.0 million for Q3 2025, versus -$80.9 million for Q2 2025 and -$199.6 million for Q1 2025.